{"id":61860,"date":"2025-02-26T12:49:47","date_gmt":"2025-02-26T12:49:47","guid":{"rendered":"https:\/?p=61860"},"modified":"2025-02-26T12:53:39","modified_gmt":"2025-02-26T12:53:39","slug":"trumps-25-pharma-tariffs","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/","title":{"rendered":"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers"},"content":{"rendered":"<p>President Donald Trump\u2019s proposed 25% tariffs on pharmaceutical imports have raised concerns for Indian drugmakers that depend heavily on the U.S. market.<\/p>\n<p>Major companies such as Sun Pharma, Dr. Reddy\u2019s Laboratories, and Cipla, each deriving 30% or more of their revenue from North America\u2014could face significant cost pressures.<\/p>\n<p>This article outlines the latest financial data and market insights for these companies, examines the potential impact of the tariffs, and suggests strategic responses for mitigating risks.<\/p>\n<p>Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor\u2019s premium features. Claim your <a href=\"https:\/\/www.stocktargetadvisor.com\/pricing?utm_source=menu&amp;utm_medium=web&amp;utm_campaign=new%20year\">discount<\/a> here!<\/p>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/pricing?utm_source=menu&amp;utm_medium=web&amp;utm_campaign=new%20year\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-60717 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2025\/01\/Pricing-Page-Banner.png\" alt=\"Earning Season Offer\" width=\"900\" height=\"200\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/01\/Pricing-Page-Banner.png 900w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/01\/Pricing-Page-Banner-300x67.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/01\/Pricing-Page-Banner-150x33.png 150w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/01\/Pricing-Page-Banner-768x171.png 768w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<h2>Sun Pharmaceutical Industries Limited (Sun Pharma):<\/h2>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/Asia\/NSE\/SUNPHARMA\">Sun Pharma<\/a>, founded by Dilip Shanghvi in 1983, is the largest pharmaceutical company in India. With a global presence spanning more than 100 countries, the company\u2019s portfolio covers a wide range of therapeutic areas\u2014from psychiatry to cardiology.<\/p>\n<p><strong>Latest Financial &amp; Market Data:<\/strong><\/p>\n<ul>\n<li><strong>U.S. Market Exposure:<\/strong> Approximately 32% of Sun Pharma\u2019s revenue is derived from the U.S.<\/li>\n<li><strong>Market Reaction:<\/strong> Following tariff threat announcements, after-hours reports indicated a modest decline in share prices (Reuters data).<\/li>\n<li><strong>Key Metrics:<\/strong> With international markets contributing around 70% of its revenue, even a slight cost increase can impact profitability.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>For a broader view of the U.S. market impact, see our article on <a href=\"https:\/canadian-tariffs-impact-us-stocks\/\">Canadian tariffs&#8217; impact on US stocks<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/Asia\/NSE\/SUNPHARMA\"><img decoding=\"async\" class=\"aligncenter wp-image-61862 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2025\/02\/sta-analyst-rating-widget-2025-02-26T172800.408.png\" alt=\"\" width=\"494\" height=\"312\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/02\/sta-analyst-rating-widget-2025-02-26T172800.408.png 494w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/02\/sta-analyst-rating-widget-2025-02-26T172800.408-300x189.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/02\/sta-analyst-rating-widget-2025-02-26T172800.408-150x95.png 150w\" sizes=\"(max-width: 494px) 85vw, 494px\" \/><\/a><\/p>\n<h2>Dr. Reddy\u2019s Laboratories:<\/h2>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/RDY\">Dr. Reddy\u2019s Laboratories<\/a> is another key player among Indian pharmaceutical giants, known for its strong presence in generics as well as specialty drug segments.<\/p>\n<p><strong>Latest Financial &amp; Market Data:<\/strong><\/p>\n<ul>\n<li><strong>U.S. Market Exposure:<\/strong> The U.S. accounts for roughly 47% of Dr. Reddy\u2019s total sales, making it highly sensitive to any tariff-induced disruptions.<\/li>\n<li><strong>Recent Performance:<\/strong> Reports have shown a 4% decline in stock value to levels not seen since June, signaling investor caution amid trade policy uncertainties.<\/li>\n<\/ul>\n<p><a href=\"http:\/\/https:\/\/www.stocktargetadvisor.com\/widgets\"><img decoding=\"async\" class=\"aligncenter wp-image-61863 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2025\/02\/sta-analyst-rating-widget-2025-02-26T173025.589.png\" alt=\"\" width=\"494\" height=\"298\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/02\/sta-analyst-rating-widget-2025-02-26T173025.589.png 494w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/02\/sta-analyst-rating-widget-2025-02-26T173025.589-300x181.png 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/02\/sta-analyst-rating-widget-2025-02-26T173025.589-150x90.png 150w\" sizes=\"(max-width: 494px) 85vw, 494px\" \/><\/a><\/p>\n<h2>Cipla Limited:<\/h2>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/Asia\/NSE\/CIPLA\">Cipla<\/a> is widely recognized for its extensive portfolio in the generics market, with products spanning respiratory, oncology, and urology therapies.<\/p>\n<p><strong>Latest Financial &amp; Market Data:<\/strong><\/p>\n<ul>\n<li><strong>U.S. Market Exposure:<\/strong> Approximately 30% of Cipla\u2019s revenue comes from North America.<\/li>\n<li><strong>Recent Performance:<\/strong> Amid tariff-related uncertainties, Cipla has experienced modest declines in share prices, with supply chain concerns adding to the challenge.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>For further insights on how tariff risks could affect US-exposed stocks, read <a href=\"https:\/what-canadian-stocks-would-trumps-tariffs-hit-the-most\/\">what Canadian stocks would Trump&#8217;s tariffs hit the most<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h2>Market Reaction and Future Outlook:<\/h2>\n<p>Following initial tariff threat announcements, Reuters reported modest declines in share prices for major Indian pharma stocks. While the market has adjusted somewhat with temporary tariff delays from Canada and Mexico, uncertainty remains high.<\/p>\n<p>Industry experts warn that if tariffs are implemented fully, companies like Sun Pharma, Dr. Reddy\u2019s, and Cipla may see continued pressure on profit margins. In a scenario where U.S. import costs rise significantly, these companies could face long-term challenges, including potential supply chain disruptions and the need to invest in domestic manufacturing capacities.<\/p>\n<p>&nbsp;<\/p>\n<h2>Conclusion:<\/h2>\n<p>Trump\u2019s proposed 25% tariffs on pharmaceuticals are poised to disrupt a delicate balance for Indian generic drugmakers with heavy U.S. exposure. Sun Pharma, Dr. Reddy\u2019s Laboratories, and Cipla each face unique challenges based on their market reliance and operational models.<\/p>\n<p>For investors and policymakers, close attention to evolving trade policies is critical. Stakeholders should be prepared for both immediate market volatility and longer-term structural changes in the pharmaceutical supply chain.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>President Donald Trump\u2019s proposed 25% tariffs on pharmaceutical imports have raised concerns for Indian drugmakers that depend heavily on the U.S. market. Major companies such&#8230;<\/p>\n","protected":false},"author":17,"featured_media":61865,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-61860","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers<\/title>\n<meta name=\"description\" content=\"Discover how Trump&#039;s proposed 25% tariffs on pharmaceutical imports could affect leading Indian drugmakers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers\" \/>\n<meta property=\"og:description\" content=\"Discover how Trump&#039;s proposed 25% tariffs on pharmaceutical imports could affect leading Indian drugmakers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-26T12:49:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-26T12:53:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/02\/STAs-Blog-Images-2025-02-26T174336.522-1024x536.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"536\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers\",\"datePublished\":\"2025-02-26T12:49:47+00:00\",\"dateModified\":\"2025-02-26T12:53:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/\"},\"wordCount\":569,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/\",\"name\":\"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2025-02-26T12:49:47+00:00\",\"dateModified\":\"2025-02-26T12:53:39+00:00\",\"description\":\"Discover how Trump's proposed 25% tariffs on pharmaceutical imports could affect leading Indian drugmakers.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers","description":"Discover how Trump's proposed 25% tariffs on pharmaceutical imports could affect leading Indian drugmakers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/","og_locale":"en_US","og_type":"article","og_title":"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers","og_description":"Discover how Trump's proposed 25% tariffs on pharmaceutical imports could affect leading Indian drugmakers.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2025-02-26T12:49:47+00:00","article_modified_time":"2025-02-26T12:53:39+00:00","og_image":[{"width":1024,"height":536,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/02\/STAs-Blog-Images-2025-02-26T174336.522-1024x536.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers","datePublished":"2025-02-26T12:49:47+00:00","dateModified":"2025-02-26T12:53:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/"},"wordCount":569,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/","name":"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2025-02-26T12:49:47+00:00","dateModified":"2025-02-26T12:53:39+00:00","description":"Discover how Trump's proposed 25% tariffs on pharmaceutical imports could affect leading Indian drugmakers.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/trumps-25-pharma-tariffs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Trump\u2019s 25% Pharma Tariffs: Impact on Top Indian Drugmakers"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/61860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=61860"}],"version-history":[{"count":3,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/61860\/revisions"}],"predecessor-version":[{"id":61868,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/61860\/revisions\/61868"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/61865"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=61860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=61860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=61860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}